Annexe Formulation Private Limited
About Annexe Formulation Private Limited
Data last updated:
Annexe Formulation Private Limited is a private limited company based in Yamuna Nagar, Haryana, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 21 April 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24230HR2021PTC094645.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Vikas and Vikram Monga.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 754 Luxmi Garden, Yamuna Nagar, Haryana, India – 135001.
As per the financials filed for FY 2025, the company reported a revenue of ₹14.21 Lakh, a decline of 27% compared to the previous year. For the same year it recorded a net loss of ₹2.05 Lakh (net margin -14.5%) and EBITDA of -₹2.05 Lakh (EBITDA margin -14.5%). Revenue has grown at a compounded annual rate (CAGR) of 175% over three years.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address754 Luxmi Garden, Yamuna Nagar, Haryana, India – 135001
- IndustryChemicals, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Annexe Formulation Private Limited
The main business activity of Annexe Formulation is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Annexe Formulation Private Limited FY 2025 filings available
Annexe Formulation Private Limited reported revenue of ₹14.21 Lakh (down 27% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Annexe Formulation Private Limited
Revenue fell 27% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 175%. EBITDA rose 47% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Annexe Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• |
| EBITDA | -₹2.05 Lakh | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹2.05 Lakh | •••• | •••• | •••• |
| Balance Sheet | ||||
| Share Capital | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• |
Financial Ratios of Annexe Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | -14.5% | •••• | •••• | •••• |
| Net Profit Margin | -14.5% | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• |
| Liquidity and Debt | ||||
| Current Ratio | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• |
| Efficiency and Growth | ||||
| Asset Turnover | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Annexe Formulation are in the company report.
Financial statements from FY 2022
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Annexe Formulation Private Limited
Annexe Formulation Private Limited is compared with the companies closest to it by revenue in the same principal business activity (Manufacture of basic pharmaceutical products and pharmaceutical preparations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Illcure Formulation Private Limited | ₹14.51 Lakh (FY 2025) | •••• | •••• | 15.0% | •••• | Lucknow, Uttar Pradesh, India |
| Strix Technologies Private Limited | ₹14.4 Lakh (FY 2025) | •••• | •••• | -82.0% | •••• | Delhi, India |
| First Ray Healthcare Private Limited | ₹14.35 Lakh (FY 2024) | •••• | •••• | •••• | Ahmedabad, Gujarat, India | |
| Matri Bio Life Private Limited | ₹14.23 Lakh (FY 2025) | •••• | •••• | 164.0% | •••• | Noida, Uttar Pradesh, India |
| Akron Consumer Care Private Limited | ₹14.22 Lakh (FY 2025) | •••• | •••• | -53.0% | •••• | Muppalla, Andhra Pradesh, India |
| Annexe Formulation Private Limited this company | ₹14.21 Lakh (FY 2025) | •••• | •••• | -27.0% | •••• | Yamuna Nagar, Haryana, India |
| Malaivel Herbal Pharma Private Limited | ₹14.1 Lakh (FY 2024) | •••• | •••• | -64.0% | •••• | Karivalamvanthanallur, Tamil Nadu, India |
| Blue Concept Ventures Private Limited | ₹14.07 Lakh (FY 2024) | •••• | •••• | •••• | Hyderabad, Telangana, India | |
| Harmeda Healthcare Private Limited | ₹13.98 Lakh (FY 2025) | •••• | •••• | •••• | Mohali, Punjab, India | |
| Mindswift Pharmaceuticals Private Limited | ₹13.97 Lakh (FY 2025) | •••• | •••• | 35.0% | •••• | Pune, Maharashtra, India |
| Dr. Memon Lab Private Limited | ₹13.9 Lakh (FY 2025) | •••• | •••• | 44.0% | •••• | Patna, Bihar, India |
Peers are the five companies nearest above and the five nearest below Annexe Formulation by revenue in the same principal business activity (Manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Annexe Formulation Private Limited
Annexe Formulation has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas | Director | 21 Apr 2021 | 5 Years 5 Months | Current |
| Vikram Monga | Director | 21 Apr 2021 | 5 Years 5 Months | Current |
Charges & Borrowings of Annexe Formulation Private Limited
Annexe Formulation Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Annexe Formulation Private Limited
Employment history and EPFO contributions of people linked to Annexe Formulation.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Annexe Formulation Private Limited
Annexe Formulation Private Limited has 4 board changes on record since 2021: 2 appointments and 2 cessations. The latest: Deepak Sharma ceased to be Director on 28 Mar 2024.
Credit Ratings, Litigation & Regulatory Alerts for Annexe Formulation Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Annexe Formulation Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Annexe Formulation Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Annexe Formulation Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Annexe Formulation Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Annexe Formulation Private Limited
Annexe Formulation is an active private limited company based in Yamuna Nagar, Haryana, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 21 April 2021 (5+ years old) and is registered under CIN U24230HR2021PTC094645.
Annexe Formulation reported revenue of ₹14.21 Lakh for FY 2025 (down 27% YoY).
Annexe Formulation has 2 current directors:
- Vikas - Director
- Vikram Monga - Director
Annexe Formulation reported a net loss of ₹2.05 Lakh (net margin -14.5%) and EBITDA of -₹2.05 Lakh (EBITDA margin -14.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Annexe Formulation is 175% over three years. In the latest year (FY 2025) revenue fell 27%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Annexe Formulation is U24230HR2021PTC094645. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Annexe Formulation was incorporated on 21 April 2021, making it 5+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Annexe Formulation by revenue are Illcure Formulation Private Limited, Strix Technologies Private Limited, First Ray Healthcare Private Limited, Matri Bio Life Private Limited, Akron Consumer Care Private Limited and 5 more, all in the same principal business activity (Manufacture of basic pharmaceutical products and pharmaceutical preparations).
Deepak Sharma ceased to be Director on 28 Mar 2024. Saurabh Dhall ceased to be Director on 28 Mar 2024. Vikas was appointed as Director on 21 Apr 2021. Annexe Formulation has 4 board changes on record in total.
The registered office of Annexe Formulation is at 754 Luxmi Garden, Yamuna Nagar, Haryana, India – 135001.
Annexe Formulation has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh.